Tag:
vandetanib
Latest Headlines
Latest Headlines
AstraZeneca wins EMA backing for thyroid cancer drug
AstraZeneca ( $AZN ) has gained support for its cancer drug vandetanib from European regulators, paving the way for a potential approval of the drug in the EU for advanced forms medullary thyroid
AZ wins tightly-limited FDA OK for new thyroid cancer drug
AstraZeneca ( $AZN ) may have missed the blockbuster opportunity of treating lung cancer with vandetanib, but it picked up a significant consolation prize yesterday when the FDA approved the treatment
Panel back's AZ's ($AZN) thyroid cancer drug vandetanib
AstraZeneca ( $AZN ) has won an expert panel's backing for vandetanib, a treatment for a rare type of thyroid cancer, called inoperable medullary thyroid cancer, which has locally advanced or
FDA cites vandetanib toxicity ahead of AZ panel review
With a panel of experts gathering on Thursday to review AstraZeneca's ( $AZN ) experimental thyroid cancer drug vandetanib, FDA staffers today unveiled their concerns about the risk of high levels of
AZ pulls apps for once-promising cancer drug
AstraZeneca's string of regulatory successes has been broken--snapped by its decision to pull marketing applications in the U.S. and Europe for the cancer drug Zactima. Named by Fitch Ratings as one
Positive results for AstraZeneca's lung cancer drug
According to Phase II results published in the Journal of Clinical Oncology, AstraZeneca's drug vandetanib (Zactima)Â improved progression free survival in patients with advanced lung cancer.
